September 25, 2023American Heart Journal237 citationsOpen Access
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
View Full Paper
Key Points
Key points are not available for this paper at this time.
Abstract
SURPASS-CVOT will provide definitive evidence as to the CV safety and efficacy of tirzepatide as compared with dulaglutide, a GLP-1 receptor agonist with established CV benefit.
Cite This Study
Nicholls et al. (2023) studied this question.